173 related articles for article (PubMed ID: 18490253)
1. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Miceli T; Colson K; Gavino M; Lilleby K;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):13-20. PubMed ID: 18490253
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Smith LC; Bertolotti P; Curran K; Jenkins B;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):37-52. PubMed ID: 18490256
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Rome S; Doss D; Miller K; Westphal J;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):21-8. PubMed ID: 18490254
[TBL] [Abstract][Full Text] [Related]
4. Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Faiman B; Bilotti E; Mangan PA; Rogers K;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):53-63. PubMed ID: 18490257
[TBL] [Abstract][Full Text] [Related]
5. Management of side effects of novel therapies for multiple myeloma: consensus statements developed by the International Myeloma Foundation's Nurse Leadership Board.
Bertolotti P; Bilotti E; Colson K; Curran K; Doss D; Faiman B; Gavino M; Jenkins B; Lilleby K; Love G; Mangan PA; McCullagh E; Miceli T; Miller K; Rogers K; Rome S; Sandifer S; Smith LC; Tariman JD; Westphal J
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):9-12. PubMed ID: 18490252
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Tariman JD; Love G; McCullagh E; Sandifer S;
Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):29-36. PubMed ID: 18490255
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Tariman JD
Clin J Oncol Nurs; 2007 Aug; 11(4):569-74. PubMed ID: 17723971
[TBL] [Abstract][Full Text] [Related]
8. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
Dasanu CA; Alexandrescu DT
Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
10. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.
Nucci M; Anaissie E
Clin Infect Dis; 2009 Oct; 49(8):1211-25. PubMed ID: 19769539
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
12. Sexual dysfunction in multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.
Richards TA; Bertolotti PA; Doss D; McCullagh EJ;
Clin J Oncol Nurs; 2011 Aug; 15 Suppl():53-65. PubMed ID: 21816710
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma.
Singhal S; Mehta J
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1322-30. PubMed ID: 17699365
[TBL] [Abstract][Full Text] [Related]
15. Mobility and safety in the multiple myeloma survivor: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.
Rome SI; Jenkins BS; Lilleby KE;
Clin J Oncol Nurs; 2011 Aug; 15 Suppl():41-52. PubMed ID: 21816709
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
17. New drugs in multiple myeloma.
Berenson JR; Yellin O
Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
[TBL] [Abstract][Full Text] [Related]
18. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Lonial S; Cavenagh J
Br J Haematol; 2009 Jun; 145(6):681-708. PubMed ID: 19344388
[TBL] [Abstract][Full Text] [Related]
19. Routine health maintenance in patients living with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.
Bilotti E; Gleason CL; McNeill A;
Clin J Oncol Nurs; 2011 Aug; 15 Suppl():25-40. PubMed ID: 21816708
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
